

Maternal and Foetal Outcome in Eclampsia Retrospective Study

Dr. M. Bansal¹

¹ GOVT. MEDICAL COLLEGE ASSOCIATED WITH MAHARANI HOSPITAL,

Received: 12 December 2015 Accepted: 2 January 2016 Published: 15 January 2016

Abstract

Eclampsia is the onset of seizures (convulsions) in a woman with pre-eclampsia. Pre-eclampsia is a disorder of pregnancy in which there is high blood pressure and either large amounts of protein in the urine or other organ dysfunction. Onset may be before, during, or after delivery. Most often it is during the second half of pregnancy. The seizures are of the tonic-clonic type and typically last about a minute. Following the seizure there is typically either a period of confusion or coma. Pre-eclampsia is estimated to affect about 5

Index terms—

1 I. Introduction

hough by the end of 20 th century, eclampsia has become almost unknown to obstetrician in the developed countries. It is still remains an important factor of maternal and perinatal morbidity and mortality in the developing countries like India.

Eclampsia is the onset of seizures (convulsions) in a woman with pre-eclampsia.

Pre-eclampsia is a disorder of pregnancy in which there is high blood pressure and either large amounts of protein in the urine or other organ dysfunction. Onset may be before, during, or after delivery.

Most often it is during the second half of pregnancy. The seizures are of the tonic-clonic type and typically last about a minute. Following the seizure there is typically either a period of confusion or coma.

Pre-eclampsia is estimated to affect about 5% of deliveries while eclampsia affects about 1.4% of deliveries. In the developed world rates are about 1 in 2,000 deliveries due to improved medical care. Hypertensive disorders of pregnancy are one of the most common causes of death in pregnancy.

They resulted in 29,000 deaths in 2013 -down from 37,000 deaths in 1990. Around one percent of women with eclampsia die.

The word eclampsia is from the Greek term for lightning. The first known description of the condition was by Hippocrates in the 5th century BCE.

Typically the pregnant woman develops hypertension and proteinuria before the onset of a convulsion, the hallmark of eclampsia. Other cerebral signs may immediately precede the convulsion, such as nausea, vomiting, headaches, and cortical blindness.

If the complication of multi-organ failure ensues, signs and symptoms of those failing organs will appear, such as abdominal pain, jaundice, shortness of breath, and diminished urine output.

The fetus may develop intrauterine growth retardation, and with maternal convulsions, bradycardia, and fetal distress. Placental bleeding, and placental abruption may also occur.

Sometimes the pregnant woman becomes comatose without preceding convulsions. Upon awakening from the coma, some experience amaurosis fugax: a "dark" and "fleeting" unilateral temporary blindness.

2 II. Material and Methods

This study was carried out in the department of Obs and Gyn, GMC Jagdalpur, Chattisgarh.

3 IV. Discussion

All cases including antenatal and postnatal eclampsia were received standard Pritchard regimen with MgSo4. (loading 4 gm iv followed by 5 gm im on each alternate buttock).

Induction of labour was done in all antenatal eclampsia irrespective of gestation age.

Monitoring of labour was carefully done, simultaneously investigation was send and complication of ecalmpsia also noted which leads to maternal morbidity and mortality.

All patients were derived within 24 hours of induction of labour.

Normal vaginal delivery occurs in 48(87.27%) cases and LSCS was performed in 3 (5.45%) cases in view of foetal distress.

Out of Total Deliveries, 24 babies was live birth and 27 babies was IUD and perinatal mortality is around 53%.

Out of 66 cases of ecalmpsia, 59 patients were discharge after 1 week without any complication, one patient was absconded after two days of delivery and 6 cases had mortality.

Out of 6 cases 2 patient were expired due to massive PPH, 2 due to ARF, one due to CVA and one due to DIC.

4 V. Conclusion

In developed countries, incidence of eclampsia is markedly reduced over last 50 years. But in developing countries like ours-incidence is very high ranging from 0.5 to 1.8%. In remote places, however incidence is > 4%.

In our study incidence is 2.31%. This is mainly due to lack of awareness about disease, women illiteracy, poor transport facilities and delayed referral. Maternal mortality in the present study is 9%.

Most of the Indian reports, Maternal mortality is between 8-14%.

The three delays framework commonly used to understand contribution to maternal death are ? Phase I delay-Delay in deciding to seek care on part of patient and family. Incidence of eclampsia should be reduced so as to reduce the maternal mortality and improve fetal outcome. Despite the focus on maternal health over last 50 years antenatal care is very low. It is necessary to create awareness among society and to bring quality care in reach of those who need it.

In 21 st century we really don't want any single mother to die of eclampsia.

5 Volume XVI Issue III Version I

1 2

¹© 2 016 Global Journals Inc. (US) Maternal and Foetal Outcome in Eclampsia Retrospective Study

²© 2016 Global Journals Inc. (US) Maternal and Foetal Outcome in Eclampsia Retrospective Study

were gravida two and 14 cases were more than three gravida.

55 (83.33%) cases of antenatal eclampsia and 11(17.66%) cases of postnatal eclampsia were reported to the hospital.

Out of antenatal eclampsia, 34 (61.8%) cases were full term (37 weeks completed) and 21 (38.18%) were preterm.

T

III. Observation

The patients were analysed with respect to age, parity, booked/unbooked status, gestational age, type of eclampsia, mode of delivery and outcome of mother and fetus

All patients with eclampsia has received standard Pritchard regimen with MgSo4.

Out of 2856 deliveries in year 2013-14, 66 patients were admitted with eclampsia, so overall incidence of eclampsia is 2.31%.

This hospital is located in most remote area of chattisgarh and most of the patients are coming from rural area.

Area wise distribution of eclampsia, from rural area, 56 cases (84.84%) and urban area 10 cases (15.15%) were recorded.

Age of patients	Age	Number of cases
18-20 yrs		25
20-25 yrs		28
25-30 yrs		10
30-35 yrs		03
Most of the eclampsia patients were reported with age between 20-25 yrs and 18-20 yrs i.e. 28, 25 respectively		
Cases Percentage		
Primigravida	46	69.7
Multigravida	20	30.3
46(69.7%) patients were primigravida and 20(30.3%) case were multigravida, including 6 cases		

Figure 1:

Our goal is to reduce the incidence and so the
maternal mortality
But how????
? Early detection of PIH and continous followup.
? Creating awareness among family members and
patients for the disease and its deadly outcome.
? Creating awareness among health personals
including mitanins and dais.(ASHA workers)
? Access to transport facility
? Timely referral is very important.
? Basic t/t at primary level specially at PHC & CHC
level. How to prevent???

Year 2016
2
Volume XVI Issue
III Version I
D D D D) E
(
Medical Research
Global Journal of
? Phase III delay-
Delay in receiving
adequate care at
the facility.

Figure 2:

[Smith et al.] , Jm; Smith , Lowe , J; Rf; Fullerton , S M Currie .

[Abalos and Cuesta] , E; Abalos , C Cuesta .

[Mcdonald et al. (2012)] ‘A systematic review of maternal and infant outcomes following magnesium sulfate for preeclampsia/eclampsia in real-world use’. Mcdonald , O; Sd; Lutsiv , N; Dzaja , L Duley . *Gynaecology and Obstetrics* August 2012. 118 (2) p. . (International journal of gynaecology and obstetrics: the official organ of the International Federation of)

[Li et al. (2003)] ‘Adrenomedullin is decreased in preeclampsia because of failed response to epidermal growth factor and impaired syncytialization’. H Li , J Dakour , S Kaufman , L J Guilbert , B Winkler-Lowen , D W Morrish . *Hypertension* November 2003. 42 (5) p. .

[Mohler ()] *Advanced Therapy in Hypertension and Vascular Disease*, Emile R Mohler . 2006. PMPH-USA. p. .

[Harris and Felker-Kantor (2013)] ‘An integrative review of the side effects related to the use of magnesium sulfate for pre-eclampsia and eclampsia management’. L Harris , E Felker-Kantor . *BMC pregnancy and childbirth* 5 February 2013. 13 p. 34.

[Cunningham et al. (1995)] ‘Blindness associated with preeclampsia and eclampsia’. F G Cunningham , C O Fernandez , C Hernandez . *American journal of obstetrics and gynecology* Apr 1995. 172 p. . (Pt 1)

[Cipolla (2007)] ‘Cerebrovascular function in pregnancy and eclampsia’. M J Cipolla . *Hypertension* July 2007. 50 (1) p. .

[Richards et al. (1988)] ‘Clinicopathological study of neurological complications due to hypertensive disorders of pregnancy’. A Richards , D Graham , R Bullock . *J. Neurol. Neurosurg. Psychiatr* March 1988. 51 (3) p. .

[Kane et al. (2002)] ‘Contemporary Clinical Management of the Cerebral Complications of Preeclampsia’. S C Kane , A Dennis , F Da Silva Costa , L Kornman , S Brennecke . *Obstetrics and Gynecology International* 2013. 2013. January 2002. January 2002. 33 (13) p. . (Obstet Gynecol)

[Grosso et al. (2013)] ‘Global and regional estimates of preeclampsia and eclampsia: a systematic review’. Al; Grosso , D; Chou , L Say . *European journal of obstetrics, gynecology, and reproductive biology* September 2013. 170 (1) p. .

[Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study]. *GBD 2013 Mortality and Causes of Death, Collaborators*, 17 December 2014. 2013.

[Zhou et al. (1997)] ‘Human cytotrophoblasts adopt a vascular phenotype as they differentiate. A strategy for successful endovascular invasion?’. Y Zhou , S J Fisher , M Janatpour . *J. Clin. Invest* May 1997. 99 (9) p. .

[Henderson et al. (2014)] ‘Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force’. Jt; Henderson , Whitlock , E; Ep; O’connor , Senger , Jh; Ca; Thompson , Rowland , Mg . *Annals of internal medicine* May 20. 2014. 160 (10) p. .

[Lu and Nightingale (2000)] ‘Magnesium sulfate in eclampsia and pre-eclampsia: pharmacokinetic principles’. J F Lu , C H Nightingale . *Clin Pharmacokinet* April 2000. 38 (4) p. .

[Rozenberg (2006)] ‘Magnesium sulphate for the management of preeclampsia’. P Rozenberg . *Gynecol Obstet Fertil* Jan 2006. 34 (1) p. .

[Duley et al. (2010)] ‘Magnesium sulphate versus diazepam for eclampsia’. L; Duley , Henderson-Smart , Dj; Walker , D Gj; Chou . *The Cochrane database of systematic reviews* Dec 8, 2010. 12.

[Duley et al. (2010)] ‘Magnesium sulphate versus lytic cocktail for eclampsia’. L; Duley , Gülmezoglu , D Chou . *The Cochrane database of systematic reviews*, Sep 8, 2010. p. D002960.

[Duley et al. (2010)] ‘Magnesium sulphate versus phenytoin for eclampsia’. L; Duley , Henderson-Smart , D Dj; Chou . *The Cochrane database of systematic reviews*, Oct 6, 2010.

[Obstetrics ()] *McGraw-Hill Professional, Williams Obstetrics* . 2014. (th ed.)

[Roberts and Cooper (2001)] ‘Pathogenesis and genetics of pre-eclampsia’. J M Roberts , D W Cooper . *Lancet* January 2001. 357 (9249) p. .

[Lambert et al. ()] ‘Preeclampsia: an update’. G; Lambert , Brichant , G; Jf; Hartstein , V Bonhomme , ; Dewandre , Py . *Acta anaesthesiologica Belgica* 2014. 65 (4) p. .

[Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy] *Obstet Gynecol* (2013). ‘Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy’. doi:10.1097/ 01.AOG.0000437382.03963.88. *Obstet Gynecol* Nov 2013. 122 (5) p. . (Hypertension in pregnancy)

[Arulkumaran and Lightstone (2013)] ‘Severe pre-eclampsia and hypertensive crises’. N Arulkumaran , L Lightstone . *Best Practice & Research Clinical Obstetrics & Gynaecology* December 2013. 27 (6) p. .

- 127 [Sex Primes Women for Sperm (2002)] *Sex Primes Women for Sperm*, February 2002. 2007-11-19.
- 128 [Chesley et al. (1968)] 'The familial factor in toxemia of pregnancy'. L C Chesley , J E Annitto , R A Cosgrove
129 . *Obstet Gynecol* September 1968. 32 (3) p. .
- 130 [Pritchard (1955)] 'The use of the magnesium ion in the management of eclamptogenic toxemias'. J A Pritchard
131 . *Surg Gynecol Obstet* February 1955. 100 (2) p. .
- 132 [WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia. (PDF) ()] *WHO recom-*
133 *mendations for prevention and treatment of pre-eclampsia and eclampsia. (PDF)*, 2011.